Cite
HARVARD Citation
Davies, A. et al. (2019). Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet oncology. 20 (5), pp. 649-662. [Online].